Patricia A Garvie1, Joanne Lawford2, Patricia M Flynn3, Aditya H Gaur4, Marvin Belzer5, George D McSherry6, Chengcheng Hu7. 1. Division of Behavioral Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee; Department of Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee. Electronic address: patti.garvie@stjude.org. 2. Division of Behavioral Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee; Department of Infectious Disease, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Infectious Disease, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Division of Adolescent Medicine, Children's Hospital-Los Angeles, Los Angeles, California. 6. Division of Pulmonary, Allergy, Immunology Infectious Diseases, Department of Pediatrics, New Jersey Medical School, Newark, New Jersey. 7. Social Scientific Systems, Inc., PACTG Operations Center, Silver Spring, Maryland; Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts.
Abstract
PURPOSE: To obtain input from adolescents with human immunodeficiency virus-1 (HIV-1) infection to inform the design of a community-based modified directly observed therapy (MDOT) antiretroviral adherence intervention. METHODS: Pediatric AIDS Clinical Trials Group (PACTG) protocol 1036A conducted three focus groups with 17 adolescents aged 17-22 years (10 female, 65% African-American) from three geographically distinct US PACTG sites. Focus group sessions were scripted, audio-taped, and transcribed verbatim. A coding dictionary was developed and validated; Ethnograph version 5.08 was used to summarize coded data across and within the three sites. Prevalent themes were identified via frequencies and are reported as percentages. RESULTS: Adolescents provided the following specific input: the MDOT provider should be familiar with the participant and empathic; the MDOT location should be mutually agreed on, flexible, and private; and participant and provider communication should be bidirectional, preferably by phone. Ideally the MDOT program should be continued until adolescents independently demonstrate adherence and should include a weaning phase as a test of skill acquisition. The most commonly endorsed barrier to the proposed program was that MDOT would be an invasion of privacy. Initially, after introduction to the purpose of the focus group, all but one adolescent expressed the belief that MDOT could benefit persons other than themselves; however, at the conclusion of the focus group discussion, a significant shift in openness to the intervention occurred, in that 11 participants indicated they would consider participation in an MDOT program if such a program were offered. CONCLUSIONS: Focus group feedback clarified the feasibility, logistics, and patient concerns about the design and implementation of a proposed MDOT intervention for adolescents with HIV-1 infection who struggle with medication adherence.
PURPOSE: To obtain input from adolescents with human immunodeficiency virus-1 (HIV-1) infection to inform the design of a community-based modified directly observed therapy (MDOT) antiretroviral adherence intervention. METHODS: Pediatric AIDS Clinical Trials Group (PACTG) protocol 1036A conducted three focus groups with 17 adolescents aged 17-22 years (10 female, 65% African-American) from three geographically distinct US PACTG sites. Focus group sessions were scripted, audio-taped, and transcribed verbatim. A coding dictionary was developed and validated; Ethnograph version 5.08 was used to summarize coded data across and within the three sites. Prevalent themes were identified via frequencies and are reported as percentages. RESULTS: Adolescents provided the following specific input: the MDOT provider should be familiar with the participant and empathic; the MDOT location should be mutually agreed on, flexible, and private; and participant and provider communication should be bidirectional, preferably by phone. Ideally the MDOT program should be continued until adolescents independently demonstrate adherence and should include a weaning phase as a test of skill acquisition. The most commonly endorsed barrier to the proposed program was that MDOT would be an invasion of privacy. Initially, after introduction to the purpose of the focus group, all but one adolescent expressed the belief that MDOT could benefit persons other than themselves; however, at the conclusion of the focus group discussion, a significant shift in openness to the intervention occurred, in that 11 participants indicated they would consider participation in an MDOT program if such a program were offered. CONCLUSIONS: Focus group feedback clarified the feasibility, logistics, and patient concerns about the design and implementation of a proposed MDOT intervention for adolescents with HIV-1 infection who struggle with medication adherence.
Authors: Grace E Macalino; Joseph W Hogan; Jennifer A Mitty; Lauri B Bazerman; Alison K Delong; Helen Loewenthal; Angela M Caliendo; Timothy P Flanigan Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland Journal: Clin Infect Dis Date: 2007-08-13 Impact factor: 9.079
Authors: Amy Rock Wohl; Wendy H Garland; Rosa Valencia; Kathleen Squires; Mallory D Witt; Andrea Kovacs; Robert Larsen; Shannon Hader; Monique-Nicole Anthony; Paul J Weidle Journal: Clin Infect Dis Date: 2006-04-28 Impact factor: 9.079
Authors: W H Garland; A R Wohl; R Valencia; M D Witt; K Squires; A Kovacs; R Larsen; N Potterat; M-N Anthony; S Hader; P J Weidle Journal: AIDS Care Date: 2007-02
Authors: Cynthia R Pearson; Mark A Micek; Jane M Simoni; Peter D Hoff; Eduardo Matediana; Diane P Martin; Stephen S Gloyd Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Aditya H Gaur; Marvin Belzer; Paula Britto; Patricia A Garvie; Chengcheng Hu; Bobbie Graham; Michael Neely; George McSherry; Stephen A Spector; Patricia M Flynn Journal: AIDS Res Hum Retroviruses Date: 2010-09 Impact factor: 2.205
Authors: Ari S Nowacek; Shantanu Balkundi; JoEllyn McMillan; Upal Roy; Andrea Martinez-Skinner; R Lee Mosley; Georgette Kanmogne; Alexander V Kabanov; Tatiana Bronich; Howard E Gendelman Journal: J Control Release Date: 2010-11-23 Impact factor: 9.776
Authors: V G Bhat; M Ramburuth; M Singh; O Titi; A P Antony; L Chiya; E M Irusen; P P Mtyapi; M E Mofoka; A Zibeke; L A Chere-Sao; N Gwadiso; N C Sethathi; S R Mbondwana; M Msengana Journal: Eur J Clin Microbiol Infect Dis Date: 2010-05-14 Impact factor: 5.103
Authors: Qingyan Ma; Lai Sze Tso; Zachary C Rich; Brian J Hall; Rachel Beanland; Haochu Li; Mellanye Lackey; Fengyu Hu; Weiping Cai; Meg Doherty; Joseph D Tucker Journal: J Int AIDS Soc Date: 2016-10-17 Impact factor: 5.396
Authors: Olurotimi A Adejumo; Kathleen M Malee; Patrick Ryscavage; Scott J Hunter; Babafemi O Taiwo Journal: J Int AIDS Soc Date: 2015-09-16 Impact factor: 5.396